28,089 Shares in Capricor Therapeutics, Inc. $CAPR Bought by First Financial Bank Trust Division

First Financial Bank Trust Division acquired a new position in Capricor Therapeutics, Inc. (NASDAQ:CAPR) in the third quarter, HoldingsChannel.com reports. The institutional investor acquired 28,089 shares of the biotechnology company’s stock, valued at approximately $203,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in CAPR. Tower Research Capital LLC TRC grew its position in shares of Capricor Therapeutics by 280.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,748 shares of the biotechnology company’s stock worth $67,000 after buying an additional 4,976 shares during the period. KLP Kapitalforvaltning AS lifted its position in Capricor Therapeutics by 65.2% during the 2nd quarter. KLP Kapitalforvaltning AS now owns 10,900 shares of the biotechnology company’s stock valued at $108,000 after acquiring an additional 4,300 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in Capricor Therapeutics during the second quarter worth about $135,000. Stoneridge Investment Partners LLC bought a new stake in Capricor Therapeutics during the first quarter worth about $150,000. Finally, Worth Venture Partners LLC purchased a new stake in Capricor Therapeutics in the first quarter worth about $155,000. Hedge funds and other institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Trading Down 4.3%

CAPR stock opened at $26.02 on Monday. The stock’s 50 day simple moving average is $9.59 and its 200 day simple moving average is $8.82. Capricor Therapeutics, Inc. has a 12-month low of $4.30 and a 12-month high of $40.37. The stock has a market capitalization of $1.19 billion, a PE ratio of -14.46 and a beta of 0.62.

Capricor Therapeutics (NASDAQ:CAPR) last posted its earnings results on Monday, November 10th. The biotechnology company reported ($0.54) EPS for the quarter, hitting analysts’ consensus estimates of ($0.54). On average, research analysts predict that Capricor Therapeutics, Inc. will post -1.21 earnings per share for the current year.

Wall Street Analysts Forecast Growth

CAPR has been the subject of several recent research reports. Maxim Group lifted their target price on shares of Capricor Therapeutics from $25.00 to $50.00 and gave the company a “buy” rating in a report on Thursday, December 4th. Oppenheimer raised their price objective on Capricor Therapeutics from $22.00 to $54.00 and gave the company an “outperform” rating in a research report on Monday, December 8th. Alliance Global Partners reissued a “buy” rating on shares of Capricor Therapeutics in a report on Wednesday, December 3rd. Roth Capital raised their price target on Capricor Therapeutics from $12.00 to $13.00 and gave the company a “buy” rating in a report on Tuesday, November 11th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Capricor Therapeutics in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Capricor Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $37.00.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.